

LIVERPOOL REVIEWS AND IMPLEMENTATION GROUP (LRiG)

Ipilimumab for previously treated unresectable malignant melanoma

Addendum – 13 February, 2012

This report was commissioned by the NIHR HTA
Programme as project number 08/209/01

DOES NOT CONTAIN CIC/AIC



On January 24, 2012 The Liverpool Reviews and Implementation Group (LRiG) was asked to comment on the model submitted by the manufacturer of Ipilimumab that had incorporated the changes to drug price in accordance with their recently approved Patient Access Scheme.

Inserting the new drug price into the previously submitted model produced an ICER of £49,844 as reported in their submission. No other amendments were detected in the model used to generate the revised ICER.